D-0150-2024 Class II Terminated
FDA drug recall D-0150-2024 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on December 4, 2023 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated March 21, 2025). Affected quantity: 96,192 bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- December 20, 2023
- Initiation Date
- December 4, 2023
- Termination Date
- March 21, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 96,192 bottles
Product Description
Liothyronine Sodium Tablets, USP 5 mcg, 100-count bottle, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-396 191, (U.T. of D & NH), India. NDC 62756-589-88
Reason for Recall
Failed Impurities/Degradation Specifications
Distribution Pattern
Nationwide
Code Information
Lot DND0059A Expires 12/2023 Lot DND0060A Expires 12/2023 Lot DND0061A Expires 12/2023 Lot DND0062A Expires 01/2024 Lot DND0063A Expires 01/2024 Lot DND0064A Expires 01/2024 Lot DND0065A Expires 01/2024 Lot DND0180A Expires 01/2024 Lot DND0181A Expires 01/2024 Lot DND0182A Expires 01/2024 Lot DND0183A Expires 01/2024 Lot DND0184A Expires 01/2024 Lot DND0597A Expires 02/2024